Selecta Biosciences, Inc. (SELB) financial statements (2022 and earlier)

Company profile

Business Address 65 GROVE STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments128,055138,68589,89337,40396,56284,141
Cash and cash equivalents114,057138,68589,89337,40370,62258,656
Short-term investments13,998   25,94025,485
Restricted cash and investments  279 7678
Receivables9,9147,2245,000 63215
Other undisclosed current assets6,4745,4341,4954,6731,9792,382
Total current assets:144,443151,34396,66742,07698,68086,816
Noncurrent Assets
Operating lease, right-of-use asset9,82910,948301
Property, plant and equipment2,1421,3951,2222,1272,0912,047
Restricted cash and investments1,3791,3791,379279329316
Other noncurrent assets     122
Other undisclosed noncurrent assets2,090370    
Total noncurrent assets:15,44014,0922,9022,4062,4202,485
TOTAL ASSETS:159,883165,43599,56944,482101,10089,301
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,3588,58913,99212,80010,1867,803
Accounts payable2244435001,1001,6063,882
Accrued liabilities10,5338,14613,49211,7008,5803,921
Taxes payable601     
Deferred revenue53,88372,0501,674
Debt5,961 19,27721,385 4,067
Deferred revenue and credits7871,836
Contract with customer, liability959
Other undisclosed current liabilities1,049908    
Total current liabilities:72,25181,54734,94335,14410,97313,706
Noncurrent Liabilities
Long-term debt and lease obligation28,27134,440  21,0427,977
Long-term debt, excluding current maturities19,67324,793  21,0427,977
Operating lease, liability8,5989,647 
Liabilities, other than long-term debt11,41738,74614,68014,75617,27112,661
Deferred revenue and credits16,07012,661
Deferred revenue11,41738,74614,680
Contract with customer, liability13,818
Deferred rent credit   34
Other liabilities   9041,201 
Other undisclosed noncurrent liabilities25,42328,70841,549   
Total noncurrent liabilities:65,111101,89456,22914,75638,31320,638
Total liabilities:137,362183,44191,17249,90049,28634,344
Stockholders' equity
Stockholders' equity attributable to parent22,521(18,006)8,397(5,418)51,81454,957
Common stock12119331
Additional paid in capital457,391391,175348,664279,539273,128211,125
Accumulated other comprehensive loss(4,566)(4,563)(4,523)(4,557)(4,420)(4,518)
Accumulated deficit(430,316)(404,629)(335,753)(280,403)(216,897)(151,576)
Receivable from shareholders or affiliates for issuance of capital stock     (75)
Total stockholders' equity:22,521(18,006)8,397(5,418)51,81454,957
TOTAL LIABILITIES AND EQUITY:159,883165,43599,56944,482101,10089,301

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues85,07716,5976,6779032078,083
Gross profit:85,07716,5976,6779032078,083
Operating expenses(89,674)(73,418)(59,132)(65,925)(63,991)(42,753)
Operating loss:(4,597)(56,821)(52,455)(65,022)(63,784)(34,670)
Nonoperating income (expense)59405(519)1,180342(287)
Investment income, nonoperating442608341,050617234
Foreign currency transaction gain (loss), before tax 56(47)120(123)(525)
Other nonoperating income (expense)1589(1,306)10(152)4
Interest and debt expense(2,844)(2,017)(1,519)(1,494)(1,879)(1,253)
Loss from continuing operations before equity method investments, income taxes:(7,382)(58,433)(54,493)(65,336)(65,321)(36,210)
Other undisclosed loss from continuing operations before income taxes(2,339)     
Loss from continuing operations before income taxes:(9,721)(58,433)(54,493)(65,336)(65,321)(36,210)
Income tax expense(15,966)     
Net loss:(25,687)(58,433)(54,493)(65,336)(65,321)(36,210)
Other undisclosed net loss attributable to parent (10,443)(857)   
Net loss attributable to parent:(25,687)(68,876)(55,350)(65,336)(65,321)(36,210)
Preferred stock dividends and other adjustments     (4,566)
Net loss available to common stockholders, diluted:(25,687)(68,876)(55,350)(65,336)(65,321)(40,776)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(25,687)(58,433)(54,493)(65,336)(65,321)(36,210)
Other comprehensive income (loss)   (137) 468
Comprehensive loss:(25,687)(58,433)(54,493)(65,473)(65,321)(35,742)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)(10,483)(823) 98 
Comprehensive loss, net of tax, attributable to parent:(25,690)(68,916)(55,316)(65,473)(65,223)(35,742)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: